U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H32N2O4.2H2O
Molecular Weight 460.5631
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALVIMOPAN

SMILES

O.O.C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C3=CC=CC(O)=C3

InChI

InChIKey=USPVLEIQIUNQGE-DBFLIVQGSA-N
InChI=1S/C25H32N2O4.2H2O/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19;;/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30);2*1H2/t18-,20-,25+;;/m0../s1

HIDE SMILES / InChI
Molecular Formula C25H32N2O4
Molecular Weight 424.5326
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8057274 | http://adisinsight.springer.com/drugs/800003539

Alvimopan (LY246736, ADL 8-2698, trade name Entereg) is a potent, peripherally selective mu-opioid receptor antagonist. Alvimopan was developed by Adolor Corporation (now Cubist Pharmaceuticals) and GlaxoSmithKline for the treatment of postoperative ileus. Postoperative ileus is the impairment of gastrointestinal motility after intra-abdominal surgery or other non-abdominal surgeries. This may potentially delay gastrointestinal recovery and hospital discharge until its resolution. Morphine and other mu-opioid receptor agonists are universally used for the treatment of acute postsurgical pain; however, they are known to have an inhibitory effect on gastrointestinal motility and may prolong the duration of postoperative ileus. Following oral administration, alvimopan antagonizes the peripheral effects of opioids on gastrointestinal motility and secretion by competitively binding to gastrointestinal tract mu-opioid receptors.

CNS Activity

Originator

Eli Lilly
237
Curator's Comment: # Eli Lilly

Approval Year

2008
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2760
 0.77 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8360
ENTEREG

Approved Use

ENTEREG is a peripherally acting μ-opioid receptor antagonist indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.

Launch Date

1.21124159E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.98 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
40.2 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
20%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
12 mg 2 times / day multiple, oral
dose: 12 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALVIMOPAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
120 mg single, oral
Highest studied dose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
48 mg 1 times / day multiple, oral
Highest studied dose
Dose: 48 mg, 1 times / day
Route: oral
Route: multiple
Dose: 48 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
healthy, adult
Health Status: healthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Other AEs: Ascites, Ileus...
Other AEs:
Ascites (serious, 1 patient)
Ileus (serious, 1 patient)
Electrolyte imbalance (serious, 1 patient)
Failure to thrive (serious, 1 patient)
Syncope (serious, 1 patient)
Wound infection (serious, 2 patients)
Wound complication (serious, 1 patient)
Mania (serious, 1 patient)
Hypertension (below serious, 3 patients)
Constipation (below serious, 18 patients)
Diarrhea (below serious, 6 patients)
Dyspepsia (below serious, 1 patient)
Nausea (below serious, 20 patients)
Vomiting (below serious, 9 patients)
Anorexia (below serious, 4 patients)
Esophagitis (below serious, 1 patient)
Gastroparesis (below serious, 1 patient)
Weight loss (below serious, 3 patients)
Leukocytosis (below serious, 4 patients)
International normalized ratio increased (below serious, 1 patient)
Electrolyte imbalance (below serious, 8 patients)
Hypomagnesemia (below serious, 2 patients)
Elevated liver enzymes (below serious, 2 patients)
Delirium (below serious, 3 patients)
Insomnia (below serious, 1 patient)
Sensory neuropathy (below serious, 3 patients)
Cystostomy (below serious, 1 patient)
Pelvic abscess (below serious, 1 patient)
Urinary tract obstruction (below serious, 1 patient)
Allergic reaction to chemotherapy (below serious, 1 patient)
Pneumonitis (below serious, 2 patients)
Pneumothorax (below serious, 2 patients)
Wound infection (below serious, 7 patients)
Skin infection (below serious, 2 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
AEs

AEs

AESignificanceDosePopulation
Allergic reaction to chemotherapy below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Cystostomy below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Dyspepsia below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Esophagitis below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Gastroparesis below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Insomnia below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
International normalized ratio increased below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Pelvic abscess below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Urinary tract obstruction below serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Constipation below serious, 18 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Elevated liver enzymes below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Hypomagnesemia below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Pneumonitis below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Pneumothorax below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Skin infection below serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Nausea below serious, 20 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Delirium below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Hypertension below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Sensory neuropathy below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Weight loss below serious, 3 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Anorexia below serious, 4 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Leukocytosis below serious, 4 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Diarrhea below serious, 6 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Wound infection below serious, 7 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Electrolyte imbalance below serious, 8 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Vomiting below serious, 9 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Ascites serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Electrolyte imbalance serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Failure to thrive serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Ileus serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Mania serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Syncope serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Wound complication serious, 1 patient
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Wound infection serious, 2 patients
12 mg 2 times / day steady, oral
Dose: 12 mg, 2 times / day
Route: oral
Route: steady
Dose: 12 mg, 2 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
unhealthy
n = 66
Health Status: unhealthy
Condition: ovarian cancer
Population Size: 66
Sources:
https://clinicaltrials.gov/ct2/show/NCT01704651
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1579
inhibitor
1752

inducer
383
inhibitor
1837
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2A6
704

CYP2B6
799

CYP2C8
901

CYP2C19
1463

CYP2E1
876

P-gp
1437
CYP
266

P-gp
1527
CYP1A2
689

CYP2B6
538

CYP2C19
290

CYP3A4/5
120
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1673
 no [IC50 >50 uM]
CYP2A6
736
 no [IC50 >50 uM]
CYP2B6
985
 no [IC50 >50 uM]
CYP2C19
1537
 no [IC50 >50 uM]
CYP2C8
955
 no [IC50 >50 uM]
CYP2C9
1803
 no [IC50 >50 uM]
CYP2D6
1875
 no [IC50 >50 uM]
CYP2E1
964
 no [IC50 >50 uM]
CYP3A4
1909
 no [IC50 >50 uM]
CYP1A2
1673
 no
CYP2B6
985
 no
CYP2C19
1537
 no
CYP2C9
1803
 no
CYP3A4/5
330
 no
P-gp
1626
 no
no (co-administration study)
Comment: based on study using MDCKII cells, digoxin transport not affected
Page: 66, 67
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
266
 no
P-gp
1527
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
PubMed

PubMed

TitleDatePubMed
Postoperative ileus: etiologies and interventions.
2003 Mar
Methylnaltrexone and alvimopan: economic management of opioid-induced bowel dysfunction.
2004 Apr
Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans.
2004 May 6
Alvimopan.
2005 Apr
Alvimopan, a selective peripherally acting mu-opioid antagonist.
2005 Apr
Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.
2005 Jun
[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists.
2005 Sep 27
Alvimopan: ADL 8-2698, ADL 82698, Entrareg, LY 246736.
2006
Peripheral opioids for functional GI disease: a reappraisal.
2006
Nurses are everywhere: a practical perspective on the surgical team in managing postoperative ileus.
2006 Apr
Optimizing perioperative management of patients undergoing colorectal surgery: what is new?
2006 Apr
Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients.
2006 Aug
A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.
2006 Aug
Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study.
2006 Jan
Current gut-directed therapies for irritable bowel syndrome.
2006 Jul
The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
2007 May
Mu opioid receptor antagonists: recent developments.
2007 Nov
Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review.
2007 Nov
Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use.
2007 Oct
Emerging pharmacologic options for treating postoperative ileus.
2007 Oct 15
Alvimopan: a peripherally acting mu-opioid receptor antagonist.
2007 Sep
Is alvimopan a safe and effective treatment for postoperative ileus?
2007 Sep
Opioid-induced constipation in intensive care patients: relief in sight?
2008
New approaches to the treatment of opioid-induced constipation.
2008 Aug
Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study.
2008 Aug 1
Alvimopan (Entereg) for postoperative ileus.
2008 Dec 1
The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor.
2008 Jan
Opioid-induced bowel dysfunction.
2008 Jan
Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults.
2008 Jan 23
New therapies in the treatment of postoperative ileus after gastrointestinal surgery.
2008 Jan-Feb
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
2008 Jul 15
Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus.
2008 Jun
Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
2008 Mar 15
Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials.
2008 May
Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.
2008 Nov
Development of peripheral opioid antagonists' new insights into opioid effects.
2008 Oct
Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus.
2008 Sep
New drugs: methylnaltrexone bromide, alvimopan, and rilonacept.
2008 Sep-Oct
Pharmacological management of postoperative ileus.
2009 Apr
Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus.
2009 Apr 4
Alvimopan for postoperative ileus: only one piece of the puzzle.
2009 Jul 15
Alvimopan for postoperative ileus.
2009 Jul 15
Preventing paralytic ileus: can the anesthesiologist help.
2009 Jun
Opioid receptors in the gastrointestinal tract.
2009 Jun 5
An overview of constipation and newer therapies.
2009 Jun-Jul
New drugs 09, part 1.
2009 Oct-Dec
Pharmacologic options to prevent postoperative ileus.
2009 Sep
Intensive Care Unit-acquired infection as a side effect of sedation.
2010
Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection.
2010 Jan
Patents

Patents

JP4343948B2
9
WO2007047935A1
3
WO2011161646A2
3
WO2013080221A2
3

Sample Use Guides

In Vivo Use Guide
12 mg administered 30 minutes to 5 hours prior to surgery followed by 12 mg twice daily for up to 7 days for a maximum of 15 doses
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In morphine-naive guinea pig ileum alvimopan increased, the amplitude of electrically evoked contractions and spontaneous mechanical activity.
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:30:44 UTC 2023
Edited
by admin
on Wed Jul 05 23:30:44 UTC 2023
Record UNII
677C126AET
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALVIMOPAN
DASH   HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
ENTEREG
Brand Name English
ALVIMOPAN DIHYDRATE [MI]
Common Name English
ALVIMOPAN [VANDF]
Common Name English
LY-246736
Code English
ALVIMOPAN [ORANGE BOOK]
Common Name English
ADL-8-2698
Code English
ALVIMOPAN [HSDB]
Common Name English
[[(2S)-2-[[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid dihydrate
Systematic Name English
LY-246736 DIHYDRATE
Code English
ALVIMOPAN [USAN]
Common Name English
ADL 8-2698
Code English
LY246736
Code English
ALVIMOPAN DIHYDRATE [MART.]
Common Name English
GLYCINE, N-(2-((4-(3-HYDROXYPHENYL)-3,4-DIMETHYL-1-PIPERIDINYL)METHYL)-1-OXO-3-PHENYLPROPYL)-, DIHYDRATE, (3R-(1(S*),3.ALPHA.,4.ALPHA.))-
Common Name English
ALVIMOPAN DIHYDRATE
MART.   MI  
Common Name English
Classification Tree Code System Code
WHO-VATC QA06AH02
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
NCI_THESAURUS C681
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
WHO-ATC A06AH02
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
NDF-RT N0000175691
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
Code System Code Type Description
MERCK INDEX
M1636
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C49096
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
USAN
MM-72
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
DRUG CENTRAL
143
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
DRUG BANK
DB06274
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
FDA UNII
677C126AET
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
MESH
C419502
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
ChEMBL
CHEMBL270190
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
SMS_ID
300000032193
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
PUBCHEM
5488547
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
WIKIPEDIA
ALVIMOPAN
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
EPA CompTox
DTXSID40168794
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
DAILYMED
677C126AET
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
IUPHAR
7471
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
CAS
170098-38-1
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY
RXCUI
480639
Created by admin on Wed Jul 05 23:30:44 UTC 2023 , Edited by admin on Wed Jul 05 23:30:44 UTC 2023
PRIMARY RxNorm
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of ALVIMOPAN ANHYDROUS
ANHYDROUS->SOLVATE
MU-TYPE OPIOID RECEPTOR
TARGET -> AGONIST
BINDING
Ki
DELTA-TYPE OPIOID RECEPTOR
TARGET -> AGONIST
BINDING
Ki
KAPPA-TYPE OPIOID RECEPTOR
TARGET -> AGONIST
BINDING
Ki
Related Record Type Details
Structure of ALVIMOPAN ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966